Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AstraZeneca, Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) plus Roche's Perjeta wins EU approval for first-line HER2-positive metastatic breast cancer
Antibody-drug conjugate, cancer, monoclonal antibody, breast cancer, HER2, combination therapy - Read more

Novartis licenses Alteogen ALT-B4 hyaluronidase tech for subcutaneous drug formulations, up to $3.2B
Licensing deal, drug delivery, biologics, milestone payments, royalties - Read more

NewBiologix, Synastra Biotechnology partner to develop stable rAAV cell line for DMD gene therapy
Manufacturing agreement, rare disease, gene therapy, cell therapy, drug discovery - Read more

Novacyt, Illumina enter five-year master collaboration agreement for diagnostics and DNA sequencing partnership
Research collaboration, diagnostics, DNA sequencing, genomics - Read more

Ono Pharmaceutical, Aitia partner on drug discovery for neurological diseases using causal AI technology
Drug discovery, neurological, AI/ML, target identification, research collaboration - Read more

Evotec, Plectonic Biotech collaborate to explore next-generation T-cell-engaging immunotherapy for solid tumors
Research collaboration, oncology, immunotherapy, antibody, drug discovery - Read more

Styx Biotechnologies, ZoeNCure Therapeutics partner to advance next-generation ADC pipeline to first-in-human trials
Co-development, oncology, antibody-drug conjugate, milestone payments, rare disease - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Teva Pharmaceutical's TEV-408 (anti-interleukin-15 antibody) hits primary endpoint in Ph2 celiac disease trial
Antibody, autoimmune, monoclonal antibody, celiac disease, IL-15 pathway - Read more

AstraZeneca, HUTCHMED's Tagrisso (osimertinib) plus Orpathys (savolitinib) shows Ph3 win in first-line MET-overexpressing non-small-cell lung cancer
Small molecule, cancer, tyrosine kinase inhibitor, non-small cell lung cancer, EGFR mutation, MET overexpression - Read more

Hengrui Pharmaceuticals' (Trastuzumab Rezetecan) meets primary endpoint in Ph3 trial for HER2-positive metastatic breast cancer
Antibody-drug conjugate, cancer, HER2-positive breast cancer, HER2, trastuzumab rezetecan - Read more

Simnova Biotech raises $59.5M Series B to advance off-the-shelf CAR-NK cell therapies
Cell therapy, CAR-NK, autoimmune, off-the-shelf, clinical-stage - Read more

NovaGo Therapeutics raises $30M Series B to advance spinal cord injury clinical study
Neurological, antibody, spinal cord injury, nerve regeneration, clinical-stage - Read more

Senticell raises $7M Seed funding to advance RBC-based liquid biopsy platform in oncology
Liquid biopsy, oncology, biomarker discovery, nucleic acids, clinical-stage - Read more

ARPA-H allocates $125M to five groups to build automated, distributed RNA therapy manufacturing infrastructure
RNA therapy, rare disease, biomanufacturing, regulatory - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Cellares cuts 168 U.S. jobs, downsizes operations after losing Bristol Myers Squibb cell therapy contract
Cell therapy, oncology, layoffs, operational, cost reduction - Read more

TScan Therapeutics cuts 75% of workforce, pausing blood cancer programs to prioritize solid tumor pipeline
TCR-T cell therapy, oncology, strategic, cost reduction - Read more

MHRA suspends Amgen's Tavneos for new UK patients amid pivotal trial data integrity concerns
Small molecule, autoimmune, regulatory, competitive - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here